{"transactions":[{"id":1119854,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T17:50:40.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":136681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":136681,"derivative":{"exercise_price":3.36,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":136681},"source":{"system":"sec-edgar","filing":"0000950170-25-083305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017025083305/ownership.xml","form_type":"4"}},{"id":1427790,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:03:38.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":32468,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024."}],"balance_after":32468,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":32468},"source":{"system":"sec-edgar","filing":"0000950170-24-099296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024099296/ownership.xml","form_type":"4"}},{"id":1427789,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:03:38.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":51420,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":51420,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":51420},"source":{"system":"sec-edgar","filing":"0000950170-24-099296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024099296/ownership.xml","form_type":"4"}},{"id":1427788,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:03:38.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":196666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024."}],"balance_after":196666,"derivative":{"exercise_price":3.56,"expiration_date":"2033-07-25","underlying":"Common Stock","underlying_shares":196666},"source":{"system":"sec-edgar","filing":"0000950170-24-099296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024099296/ownership.xml","form_type":"4"}},{"id":1427787,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:03:38.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32468,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":32468},"source":{"system":"sec-edgar","filing":"0000950170-24-099296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024099296/ownership.xml","form_type":"4"}},{"id":1427786,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:03:38.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51420,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":51420},"source":{"system":"sec-edgar","filing":"0000950170-24-099296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024099296/ownership.xml","form_type":"4"}},{"id":1427785,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:03:38.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":196666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-07-25","underlying":"Common Stock","underlying_shares":196666},"source":{"system":"sec-edgar","filing":"0000950170-24-099296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024099296/ownership.xml","form_type":"4"}},{"id":1482192,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T16:06:28.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":42242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of October 10, 2019, subject to the reporting person's continued service relationship through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.04,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":42242},"source":{"system":"sec-edgar","filing":"0000950170-24-072426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024072426/ownership.xml","form_type":"4"}},{"id":1482191,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-12T16:06:28.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":42242,"price":5.04,"value":212899.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":67242,"source":{"system":"sec-edgar","filing":"0000950170-24-072426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024072426/ownership.xml","form_type":"4"}},{"id":1490184,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T20:04:57.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":102225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":102225,"derivative":{"exercise_price":6.79,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":102225},"source":{"system":"sec-edgar","filing":"0000950170-24-069558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024069558/ownership.xml","form_type":"4"}},{"id":1557616,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-03-29T16:30:30.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":32468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":32468,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":32468},"source":{"system":"sec-edgar","filing":"0000950170-24-038702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000095017024038702/ownership.xml","form_type":"4"}},{"id":1872172,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T18:36:12.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":66055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":66055,"derivative":{"exercise_price":11.14,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":66055},"source":{"system":"sec-edgar","filing":"0001209191-23-033434","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000120919123033434/doc4.xml","form_type":"4"}},{"id":2068408,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Earn-out Shares","published_at":"2023-01-04T21:56:56.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":1585,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 1,109 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 1,109 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 1,109 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 1,109 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.)."}],"balance_after":302203,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001104659-23-001118","document":"tm231679-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923001118/tm231679-9_4seq1.xml","form_type":"4"}},{"id":2253665,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T17:33:34.000Z","date":"2022-05-27","kind":"grant","acquired":true,"shares":41597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":41597,"derivative":{"exercise_price":17.33,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":41597},"source":{"system":"sec-edgar","filing":"0001209191-22-032671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000120919122032671/doc4.xml","form_type":"4"}},{"id":2365779,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-01T17:36:36.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":515601,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing February 1, 2022, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":515601,"derivative":{"exercise_price":3.03,"expiration_date":"2032-02-25","underlying":"Common Stock","underlying_shares":515601},"source":{"system":"sec-edgar","filing":"0001213900-22-010138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000121390022010138/ownership.xml","form_type":"4"}},{"id":2464110,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Earn-out Shares","published_at":"2021-12-20T21:58:50.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":300618,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 210,433 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 210,433 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 210,433 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the \"Earn-out Shares\"), (i) 210,433 of which will be released from escrow if the value weighted average price (\"VWAP\") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement."}],"balance_after":300618,"derivative":{"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":300618},"source":{"system":"sec-edgar","filing":"0000899243-21-049100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049100/doc4.xml","form_type":"4"}},{"id":2464109,"issuer":{"id":108311,"kind":"organization","name":"EQRx, Inc.","symbol":"EQRX"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-20T21:58:50.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":2194500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 17, 2021, upon consummation of  the transactions (the \"Closing\" of the \"Business Combination\") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the \"Merger Agreement\") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., \"Legacy EQRx\"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 17, 2021, upon consummation of  the transactions (the \"Closing\" of the \"Business Combination\") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the \"Merger Agreement\") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., \"Legacy EQRx\"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock."}],"balance_after":2194500,"source":{"system":"sec-edgar","filing":"0000899243-21-049100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843762/000089924321049100/doc4.xml","form_type":"4"}},{"id":2701081,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-21T19:45:53.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":16000,"derivative":{"exercise_price":30.09,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-21-035115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000120919121035115/doc4.xml","form_type":"4"}},{"id":3078959,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":78793,"kind":"person","name":"Rubin Jami","position":1,"cik":"0001816484","reported_name":"Rubin Jami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T19:17:21.000Z","date":"2020-07-20","kind":"purchase","acquired":true,"shares":25000,"price":20,"value":500000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 20, 2020, the Reporting Person purchased 25,000 shares of common stock, par value $0.001 per share, of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000899243-20-019842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816484/000089924320019842/doc4.xml","form_type":"4"}}]}